Nuvation Bio

NEW YORK, NY · Founded 2018 · CIK 0001829093 · Biotech · Public

Oncology therapeutics developed through proprietary drug discovery and development platform

nuvationbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$275M
1 Form D · Oct 2020
72 months since last filing
Contracts
—
No federal contracts on record
Patents
24
3 granted · 21 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$275,348,195
Form D · SECPress

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2782Legend Biotech Corp—$350M
2783Sensei Biotherapeutics, Inc.—$349M
2784X4 Pharmaceuticals—$313M
2785Nuvation Bio—$275M
2786CELL REPROGRAMMING & THERAPEUTICS LLC——
2787Veradermics—$269M
2788Avalyn Pharma—$242M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Press

1 article · matched on company name

Founders & Team

From Form D filings · 8 related persons
  • Robert BazemoreDirector
  • Kim BlickenstaffDirector
  • Michelle DoigDirector
  • Kathryn FalbergDirector
  • David Hung, M.D.Director · Executive Officer
  • Claudio NessiDirector
  • W. VernonDirector
  • Daniel WelchDirector

Patents

USPTO · 3 granted of 24
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
  • Method For Producing 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINE Compoundsapplication
  • Heterocyclic Compounds As Bet Inhibitorsapplication
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsapplication
  • Anti-cancer Nuclear Hormone Receptor-targeting Compoundsgranted
  • Heterocyclic Compounds As Bet Inhibitorsapplication
  • Heterocyclic Compounds As Bet Inhibitorsapplication
  • SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORSapplication
  • Treating Cancers With A Cyclin-dependent Kinase Inhibitorapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.